Brown fat accompanies fewer diagnoses in cancer-centre data
Active brown fat was associated with fewer cardiovascular and psychiatric diagnoses in a retrospective study of cancer-centre patients. The single peer-reviewed investigation used imaging and clinical data, then pursued a drug association in cells and mice. These findings distinguish a human observational association from experimental results that establish no new treatment benefit in people.
Science··Night
Imaging links brown fat with diagnoses
Detectable active brown fat was associated with fewer cardiovascular and psychiatric diagnoses in a retrospective analysis of 101,243 patients. The single peer-reviewed study used data from Memorial Sloan Kettering Cancer Center, a US cancer-treatment and research institution. At least one scan detected brown fat in 8,897 people. Matching accounted for outdoor temperature and participants’ age, sex and body mass index; statistical adjustments also covered cancer-related variables.[1]
Glucose uptake supplies the activity measure
An artificial-intelligence-assisted imaging method quantified tissue activity in 8,709 people. Activity in brown fat under the armpit showed a particularly strong association with more favourable metabolic findings. Glucose uptake supplies the imaging indicator; heat production was not measured directly. The retrospective comparison establishes an association within this patient population, while cancer types, treatment and other factors remain relevant to interpreting the pattern.[1]
Losartan is tested in cells and mice
Separate experiments followed a link between taking losartan and having detectable brown fat. Brown-fat activity rose in both cell and mouse experiments with the drug; the mice also expended more energy. Those experimental findings do not demonstrate a new benefit for human weight loss or disease treatment. The human observational design cannot establish causation; prospective studies in broader populations are needed to assess how widely the associations apply.[1]
